World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: Netherlands Trial Register
Last refreshed on: 28 April 2013
Main ID:  NTR979
Date of registration: 24/05/2007
Primary sponsor: Universitair Ziekenhuis Brussel (UZB), Centrum Medische Genetica en Centrum Reproductieve Geneeskunde
Public title: Prospective randomized sibling-oocyte study using recombinant human hyaluronidase Cumulase® versus Sigma hyaluronidase in ICSI patients.
Scientific title: Prospective randomized sibling-oocyte study using recombinant human hyaluronidase Cumulase® versus Sigma hyaluronidase in ICSI patients. - N/A
Date of first enrolment: 1/5/2006
Target sample size: 135
Recruitment status: complete
URL:  http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=979
Study type:  intervention
Study design:  Randomised: Yes; Masking: None; Control: Active; Group: Parallel; Type: 2 or more arms, randomized  
Countries of recruitment
The Netherlands
Contacts
Name: Anick   Vos, De
Address:  Clinical Embryologist, Centre for Reproductive Medicine, UZ Brussel, Laarbeeklaan 101 B-1090 Brussels Belgium
Telephone: +32-2-477.66.97
Email: anick.devos@uzbrussel.be
Affiliation: 
Name: Josiane   Elst, Van der
Address:  Laboratory Director, Centre for Reproductive Medicine, UZ Brussel, Laarbeeklaan 101 B-1090 Brussels Belgium
Telephone: +32-2-477.66.90
Email: Josiane.Vanderelst@uzbrussel.be
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: Women undergoing ICSI treatment with fresh ejaculate sperm cells, no older than 38 years of age and presenting between 8 and 16 cumulus oocyte complexes(COC's) at ovum pick up.
Exclusion criteria: 1. Surgically extracted sperm preparations;

2. Embryo biopsy cycles;

3. Women older than 38 years;

4. Women with less than 8 or more than 16 COC's.


Age minimum:
Age maximum:
Gender:
Health Condition(s) or Problem(s) studied
Cumulus cell , Hyaluronidase, Intracytoplasmic sperm injection (ICSI), Prospective study

Intervention(s)
Oocyte denudation (i.e. removal of the surrounding cumulus and corona cells, in preparation to ICSI).
Primary Outcome(s)
1. Oocyte intactness after ICSI;

2. Fertilization rate.
Secondary Outcome(s)
1. Embryo development;

2. Positive hCG after embryo transfer.
Secondary ID(s)
HZ2-05-07
ISRCTN89831716
Source(s) of Monetary Support
Universitair Ziekenhuis Brussel, Centrum Medische Genetica en Centrum Reproductieve Geneeskunde, Halozyme Therapeutics Inc., San Diego, USA
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history